Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance ...

The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market value The numerous challenges plaguing the company resulted in the dilution of the stock ...

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by ...

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with overall 7% growth for the year. Shares fell more than 10% as Merck ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, has secured Merck global rights to LaNova Medicines’ PD-1xVEGF ...

On that last point, Merck has increased its payout by a decent 71% in the past five years and offers a dividend yield of 2.8% currently, which is above the S&P 500's average of 1.3%.

Merck to acquire EyeBio for a $1.3 billion upfront payment and up to $1.7 billion in future milestone payments for a potential value of $3 billion May 29, 2024 06:45 AM Eastern Daylight Time ...

Merck (MRK -0.04%) has performed poorly in the stock market this year, with the drugmaker's shares down by 5%. But zooming out helps put a different spin on this story as the pharmaceutical giant ...

An 'old-soul-in-a-new-era' model Khushhboo Kankan is the kind of woman you would like to get to know. Her Instagram feed portrays a spunky, down-to-earth girl, who trained in martial arts and once ...

In the lawsuit, Merck said drugmakers must accept price cuts of 25% to 60% or pay a "ruinous daily excise tax" for selected drugs. The negotiation will force the drugmaker to "sell its most ...

The Superior Court of New Jersey previously granted Merck a $1.4 billion payout after the pharma company sued its insurers who had denied coverage for the NotPetya attack. In appeal, eight ...

Merck’s operating margin of 30.6% over the last twelve-month period is better than 25.3% for Eli Lilly. This compares with 18.7% and 21.8% figures seen in 2019, before the pandemic, respectively.